Analysts have clear opinions on YMAB.
There are 5 analysts on the Wall offering 12 month price targets for Y-Mabs Therapeutics in the last 3 months. The average price target is $39.75 with a high forecast of $40.00 and a low forecast of $39.00. The average price target represents a 32.99% increase from the last price of $29.89.
Y-mAbs Therapeutics, Inc. (YMAB) is followed by 5 analysts on the street.
Anupam Rama from J.P. Morgan rates it a Buy with a target of $39.00.
Similarly, Last month Ram Selvaraju of H.C. Wainwright Reiterated a Buy with a target of $40.00.
The consensus on the street is Strong Buy.
What does Y-mAbs Therapeutics, Inc.(YMAB) do ?
Y-mAbs Therapeutics, Inc. is a clinical-stage biopharmaceutical company. It develops novel antibody therapeutics for oncology targets. The company’s services include discovery, protein engineering, clinical and regulatory. Y-mAbs Therapeutics was founded by Thomas Gad in April 2015 and is headquartered in New York, NY.
Y-mAbs Therapeutics, Inc. (YMAB) Insider Trades
Multiple company employees have indulged in significant insider trading. Y-mAbs Therapeutics, Inc. disclosed the following in a document filed with the US Securities and Exchange Commission (SEC):
Pres, COB, Gad Thomas : S – Sale(-$123,612) of YMAB in the trading session of 2020-01-13.
Pres, COB Gad Thomas : S – Sale(-$126,176) of YMAB in the trading session of 2019-12-16.
Pres, COB Gad Thomas : S – Sale(-$129,930) of Y-mAbs Therapeutics, Inc. in the trading session of 2019-12-02.